Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry

14 August 2017) Fabre, J.-E., Nguyen, M., Athirakul, K., Coggins, K., McNeish, J.D., Austin, S., Parise, L.K., FitzGerald, G.A., Coffman, T.M. & Koller, B.H. (2001) Activation of the murine EP3 receptor for PGE(2) inhibits cAMP production and promotes platelet aggregation. Journal of Clinical Investigation, 107, 603–610. Gross, S., Tilly, P., Hentsch, D., Vonesch, J.-L. & Fabre, J.-E. (2007) Vascular wall–produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. Journal of Experimental Medicine, 204, 311–320. Ikeda-Matsuo, Y., Tanji, H., Narumiya, S. & Sasaki, Y. (2011) Inhibition of prostaglandin E2 EP3 receptors improves stroke injury via antiinflammatory and anti-apoptotic mechanisms. Journal of Neuroimmunology, 238, 34–43. Iyu, D., Glenn, J.R., White, A.E., Johnson, A.J., Fox, S.C. & Heptinstall, S. (2010) The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function. Platelets, 21, 329–342. Saleem, S., Kim, Y.T., Maruyama, T., Narumiya, S. & Dor e, S. (2009) Reduced acute brain injury in PGE(2) EP3 receptor–deficient mice after cerebral ischemia. Journal of Neuroimmunology, 208, 87–93. Tilly, P., Charles, A.-L., Ludwig, S., Slimani, F., Gross, S., Meilhac, O., Geny, B., Stefansson, K., Gurney, M.E. & Fabre, J.-E. (2014) Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovascular Research, 101, 482–491.

[1]  P. Prandoni,et al.  Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study. , 2015, Thrombosis research.

[2]  C. Kessler,et al.  Acquired haemophilia: an overview for clinical practice , 2015, European journal of haematology.

[3]  I. Durieu,et al.  FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French ‘FEIBA dans l'hémophilie A acquise’ (FEIBHAC) registry , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  F. Pellegrini,et al.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.

[5]  J. Esser,et al.  Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) , 2012, Journal of thrombosis and haemostasis : JTH.

[6]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[7]  T. Nichols,et al.  Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  S. Sallah.  Treatment of acquired haemophilia with factor eight inhibitor bypassing activity , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.